InvestLog
Back to Market返回行情

TMCI Treace Medical Concepts, Inc.

USHealthcare
$4.32-7.30%ClosedMarket Cap: $280.3M

As of 2026-07-10 16:00

Why TMCI matters now

Treace Medical Concepts, Inc. (TMCI) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.32 with -7.30% on the session and $280.3M in market capitalization; recent performance reads 1-month +54.04% and YTD +71.02%.

The latest financial table shown here is Q1 2026, with revenue of $47.2M, net income of $-18.0M, and EPS of $-0.28. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.6%.

The latest indexable market news headline is "Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $3.00; recent insider activity includes Treace John T. filing P-Purchase. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

—

PEG

—

P/B

3.51

P/S

1.31

EV/EBITDA

-5.95

DCF Value

$-6.86

FCF Yield

-9.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

79.7%

Operating Margin

-26.9%

Net Margin

-29.4%

ROE

-69.5%

ROA

-33.2%

ROIC

-37.3%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$47.2M$-18.0M$-0.28
Q4 2025$62.5M$-9.4M$-0.15
FY 2025$212.7M$-59.0M$-0.93
Q3 2025$50.2M$-16.3M$-0.26

Analyst Ratings

Consensus

Hold

Target (Consensus)

$3.00

Target (Median)

$3.00

Target Range

$3.00 - $3.00

Strong Buy: 0Buy: 1Hold: 3Sell: 0Strong Sell: 1
Lake StreetBuy
2026-03-02
StifelHold
2026-01-07
Truist SecuritiesHold
2025-12-18
Truist SecuritiesHold
2025-11-10
JP MorganUnderweight
2025-11-07

Trading Activity

Insider Trades

Treace John T.director, 10 percent owner, officer: Chief Executive Officer
Buy2026-06-12
Treace John T.director, 10 percent owner, officer: Chief Executive Officer
Buy2026-06-12
Treace John T.director, 10 percent owner, officer: Chief Executive Officer
Buy2026-06-11
Treace John T.director, 10 percent owner, officer: Chief Executive Officer
Buy2026-06-11
Treace John T.director, 10 percent owner, officer: Chief Executive Officer
Buy2026-06-01

Related Stocks

BVS
Bioventus Inc.
$582.6M
CBLL
CeriBell, Inc.
$705.4M
EHAB
Enhabit, Inc.
$706.9M
EOLS
Evolus, Inc.
$444.5M
KIDS
OrthoPediatrics Corp.
$466.2M

Latest News

Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant SystemGlobeNewsWire · 2026-06-18
Treace to Present at the Sidoti Small Cap ConferenceGlobeNewsWire · 2026-06-11
Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewsWire · 2026-05-12
Treace Medical Concepts Q1 Earnings Call HighlightsMarketBeat · 2026-05-09
Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call TranscriptSeeking Alpha · 2026-05-08

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

—

Beta

1.41

Headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts, Inc. is an orthopedic medical device enterprise that specializes in the development, manufacturing, and commercialization of surgical tools for foot and ankle specialists throughout the United States. A cornerstone of its product line is the Lapiplasty procedure, which enables surgeons to comprehensively correct bunions in all three dimensions, thereby offering patients significant cosmetic and medical benefits. The firm also provides the Lapiplasty Mini-Incision precision system. Furthermore, its portfolio includes instruments designed to facilitate various ancillary surgical procedures, such as akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, autograft bone harvesting, and MTP fusion. Treace Medical Concepts, Inc. was established in 2013.